{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:46:34Z","timestamp":1787003194320,"version":"build-2736575974"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:00:00Z","timestamp":1723334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T00:00:00Z","timestamp":1723334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-50880-2","type":"journal-article","created":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T02:01:45Z","timestamp":1723341705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Szymon J.","family":"Szymura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soung-chul","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Parshottam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper B.","family":"Olsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon N.","family":"Crumpton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet E.","family":"Manasanch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1884-5349","authenticated-orcid":false,"given":"Larry W.","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,11]]},"reference":[{"key":"50880_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.beha.2016.08.014","volume":"29","author":"RA Kyle","year":"2016","unstructured":"Kyle, R. A., Ansell, S. M. & Kapoor, P. Prognostic factors and indications for treatment of Waldenstrom\u2019s Macroglobulinemia. Best. Pract. Rest. Clin. Haematol. 29, 179\u2013186 (2016).","journal-title":"Best. Pract. Rest. Clin. Haematol."},{"key":"50880_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"50880_CR3","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1158\/1078-0432.CCR-14-3175","volume":"22","author":"A Desrichard","year":"2016","unstructured":"Desrichard, A., Snyder, A. & Chan, T. A. Cancer neoantigens and applications for immunotherapy. Clin. Cancer Res. 22, 807\u2013812 (2016).","journal-title":"Clin. Cancer Res."},{"key":"50880_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"50880_CR5","first-page":"2268","volume":"36","author":"GT Stevenson","year":"1977","unstructured":"Stevenson, G. T., Elliott, E. V. & Stevenson, F. K. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. Fed. Proc. 36, 2268\u20132271 (1977).","journal-title":"Fed. Proc."},{"key":"50880_CR6","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/254714a0","volume":"254","author":"GT Stevenson","year":"1975","unstructured":"Stevenson, G. T. & Stevenson, F. K. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 254, 714\u2013716 (1975).","journal-title":"Nature"},{"key":"50880_CR7","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1073\/pnas.68.12.3130","volume":"68","author":"S Sirisinha","year":"1971","unstructured":"Sirisinha, S. & Eisen, H. N. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc. Natl. Acad. Sci. USA 68, 3130\u20133135 (1971).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50880_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1073\/pnas.69.6.1540","volume":"69","author":"RG Lynch","year":"1972","unstructured":"Lynch, R. G., Graff, R. J., Sirisinha, S., Simms, E. S. & Eisen, H. N. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69, 1540\u20131544 (1972).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50880_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nature21433","volume":"543","author":"MS Khodadoust","year":"2017","unstructured":"Khodadoust, M. S. et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543, 723\u2013727 (2017).","journal-title":"Nature"},{"key":"50880_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","volume":"133","author":"MS Khodadoust","year":"2019","unstructured":"Khodadoust, M. S. et al. B-cell lymphomas present immunoglobulin neoantigens. Blood 133, 878\u2013881 (2019).","journal-title":"Blood"},{"key":"50880_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","volume":"327","author":"LW Kwak","year":"1992","unstructured":"Kwak, L. W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209\u20131215 (1992).","journal-title":"N. Engl. J. Med."},{"key":"50880_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/13928","volume":"5","author":"M Bendandi","year":"1999","unstructured":"Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5, 1171\u20131177 (1999).","journal-title":"Nat. Med."},{"key":"50880_CR13","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","volume":"29","author":"SJ Schuster","year":"2011","unstructured":"Schuster, S. J. et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787\u20132794 (2011).","journal-title":"J. Clin. Oncol."},{"key":"50880_CR14","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2008.19.8903","volume":"27","author":"A Freedman","year":"2009","unstructured":"Freedman, A. et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol. 27, 3036\u20133043 (2009).","journal-title":"J. Clin. Oncol."},{"key":"50880_CR15","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","volume":"32","author":"R Levy","year":"2014","unstructured":"Levy, R. et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J. Clin. Oncol. 32, 1797\u20131803 (2014).","journal-title":"J. Clin. Oncol."},{"key":"50880_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/6995","volume":"17","author":"A Biragyn","year":"1999","unstructured":"Biragyn, A., Tani, K., Grimm, M. C., Weeks, S. & Kwak, L. W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17, 253\u2013258 (1999).","journal-title":"Nat. Biotechnol."},{"key":"50880_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1126\/science.1075565","volume":"298","author":"A Biragyn","year":"2002","unstructured":"Biragyn, A. et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298, 1025\u20131029 (2002).","journal-title":"Science"},{"key":"50880_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/sonc.2003.50073","volume":"30","author":"ED Remstein","year":"2003","unstructured":"Remstein, E. D., Hanson, C. A., Kyle, R. A., Hodnefield, J. M. & Kurtin, P. J. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom\u2019s macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol. 30, 182\u2013186 (2003).","journal-title":"Semin Oncol."},{"key":"50880_CR19","doi-asserted-by":"publisher","first-page":"815325","DOI":"10.1155\/2013\/815325","volume":"2013","author":"S Janz","year":"2013","unstructured":"Janz, S. Waldenstrom macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol. 2013, 815325 (2013).","journal-title":"ISRN Hematol."},{"key":"50880_CR20","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1038\/sj.onc.1204239","volume":"20","author":"H van Dam","year":"2001","unstructured":"van Dam, H. & Castellazzi, M. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 20, 2453\u20132464 (2001).","journal-title":"Oncogene"},{"key":"50880_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bjh.12175","volume":"160","author":"E Hebron","year":"2013","unstructured":"Hebron, E. et al. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes\/macrophages. Br. J. Haematol. 160, 779\u2013784 (2013).","journal-title":"Br. J. Haematol."},{"key":"50880_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10020-022-00534-0","volume":"28","author":"F Kayastha","year":"2022","unstructured":"Kayastha, F. et al. Novel eIF4A1 inhibitors with anti-tumor activity in lymphoma. Mol. Med. 28, 101 (2022).","journal-title":"Mol. Med."},{"key":"50880_CR23","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1074\/jbc.M806735200","volume":"284","author":"YY Lee","year":"2009","unstructured":"Lee, Y. Y., Cevallos, R. C. & Jan, E. An upstream open reading frame regulates translation of GADD34 during cellular stresses that induce eIF2alpha phosphorylation. J. Biol. Chem. 284, 6661\u20136673 (2009).","journal-title":"J. Biol. Chem."},{"key":"50880_CR24","doi-asserted-by":"publisher","first-page":"e109823","DOI":"10.15252\/embj.2021109823","volume":"41","author":"JR Kovalski","year":"2022","unstructured":"Kovalski, J. R., Kuzuoglu-Ozturk, D. & Ruggero, D. Protein synthesis control in cancer: selectivity and therapeutic targeting. EMBO J. 41, e109823 (2022).","journal-title":"EMBO J."},{"key":"50880_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ccell.2021.04.011","volume":"39","author":"C Garlanda","year":"2021","unstructured":"Garlanda, C. & Mantovani, A. Interleukin-1 in tumor progression, therapy, and prevention. Cancer Cell 39, 1023\u20131027 (2021).","journal-title":"Cancer Cell"},{"key":"50880_CR26","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","volume":"118","author":"SF Elsawa","year":"2011","unstructured":"Elsawa, S. F. et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 118, 5540\u20135549 (2011).","journal-title":"Blood"},{"key":"50880_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-015-0106-8","volume":"8","author":"J Xie","year":"2015","unstructured":"Xie, J. et al. IGF-IR determines the fates of BCR\/ABL leukemia. J. Hematol. Oncol. 8, 3 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"50880_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3816\/CLM.2009.n.010","volume":"9","author":"SF Elsawa","year":"2009","unstructured":"Elsawa, S. F. & Ansell, S. M. Cytokines in the microenvironment of Waldenstrom\u2019s macroglobulinemia. Clin. Lymphoma Myeloma 9, 43\u201345 (2009).","journal-title":"Clin. Lymphoma Myeloma"},{"key":"50880_CR29","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon, S. P. et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N. Engl. J. Med. 372, 1430\u20131440 (2015).","journal-title":"N. Engl. J. Med."},{"key":"50880_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/leu.2016.8","volume":"30","author":"KV Argyropoulos","year":"2016","unstructured":"Argyropoulos, K. V. et al. Clonal B cells in Waldenstrom\u2019s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia 30, 1116\u20131125 (2016).","journal-title":"Leukemia"},{"key":"50880_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.beha.2016.09.001","volume":"29","author":"ML Palomba","year":"2016","unstructured":"Palomba, M. L. Learning from Waldenstrom macroglobulinemia. Best. Pr. Res. Clin. Haematol. 29, 135 (2016).","journal-title":"Best. Pr. Res. Clin. Haematol."},{"key":"50880_CR32","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.19.02314","volume":"38","author":"SP Treon","year":"2020","unstructured":"Treon, S. P. et al. Genomic landscape of Waldenstrom macroglobulinemia and its impact on treatment strategies. J. Clin. Oncol. 38, 1198\u20131208 (2020).","journal-title":"J. Clin. Oncol."},{"key":"50880_CR33","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1182\/blood-2007-05-092098","volume":"110","author":"X Leleu","year":"2007","unstructured":"Leleu, X. et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 110, 4417\u20134426 (2007).","journal-title":"Blood"},{"key":"50880_CR34","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.4049\/jimmunol.177.8.5068","volume":"177","author":"DM Ray","year":"2006","unstructured":"Ray, D. M., Akbiyik, F. & Phipps, R. P. The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. J. Immunol. 177, 5068\u20135076 (2006).","journal-title":"J. Immunol."},{"key":"50880_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"50880_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10582","volume":"7","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy. Nat. Commun. 7, 10582 (2016).","journal-title":"Nat. Commun."},{"key":"50880_CR37","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","volume":"36","author":"MGM Roemer","year":"2018","unstructured":"Roemer, M. G. M. et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J. Clin. Oncol. 36, 942\u2013950 (2018).","journal-title":"J. Clin. Oncol."},{"key":"50880_CR38","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692\u2013696 (2015).","journal-title":"Nature"},{"key":"50880_CR39","doi-asserted-by":"publisher","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","volume":"112","author":"MR Green","year":"2015","unstructured":"Green, M. R. et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. USA 112, E1116\u20131125 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50880_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2643-3230.BCD-21-0075","volume":"3","author":"G Han","year":"2022","unstructured":"Han, G. et al. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. 3, 428\u2013443 (2022).","journal-title":"Blood Cancer Discov."},{"key":"50880_CR41","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1084\/jem.180.4.1329","volume":"180","author":"P Silacci","year":"1994","unstructured":"Silacci, P., Mottet, A., Steimle, V., Reith, W. & Mach, B. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J. Exp. Med. 180, 1329\u20131336 (1994).","journal-title":"J. Exp. Med."},{"key":"50880_CR42","doi-asserted-by":"publisher","first-page":"15264","DOI":"10.1074\/jbc.M100862200","volume":"276","author":"N Ghosh","year":"2001","unstructured":"Ghosh, N., Gyory, I., Wright, G., Wood, J. & Wright, K. L. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J. Biol. Chem. 276, 15264\u201315268 (2001).","journal-title":"J. Biol. Chem."},{"key":"50880_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104856","volume":"25","author":"JH Lim","year":"2022","unstructured":"Lim, J. H. et al. Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenstrom macroglobulinemia. iScience 25, 104856 (2022).","journal-title":"iScience"},{"key":"50880_CR44","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Impaired death receptor signaling in Leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552\u2013567 (2020).","journal-title":"Cancer Discov."},{"key":"50880_CR45","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"50880_CR46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"50880_CR47","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.copbio.2020.07.010","volume":"65","author":"J Chiffelle","year":"2020","unstructured":"Chiffelle, J. et al. T-cell repertoire analysis and metrics of diversity and clonality. Curr. Opin. Biotechnol. 65, 284\u2013295 (2020).","journal-title":"Curr. Opin. Biotechnol."},{"key":"50880_CR48","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1172\/JCI97454","volume":"128","author":"AB Khan","year":"2018","unstructured":"Khan, A. B. et al. Redirection to the bone marrow improves T cell persistence and antitumor functions. J. Clin. Invest. 128, 2010\u20132024 (2018).","journal-title":"J. Clin. Invest."},{"key":"50880_CR49","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.3389\/fimmu.2018.02605","volume":"9","author":"DP Saraiva","year":"2018","unstructured":"Saraiva, D. P., Jacinto, A., Borralho, P., Braga, S. & Cabral, M. G. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients\u2019 Response to Neoadjuvant Chemotherapy. Front. Immunol. 9, 2605 (2018).","journal-title":"Front. Immunol."},{"key":"50880_CR50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fimmu.2013.00020","volume":"4","author":"EH Kim","year":"2013","unstructured":"Kim, E. H. & Suresh, M. Role of PI3K\/Akt signaling in memory CD8 T cell differentiation. Front. Immunol. 4, 20 (2013).","journal-title":"Front. Immunol."},{"key":"50880_CR51","doi-asserted-by":"publisher","first-page":"239368","DOI":"10.1155\/2012\/239368","volume":"2012","author":"A Visekruna","year":"2012","unstructured":"Visekruna, A., Volkov, A. & Steinhoff, U. A key role for NF-kappaB transcription factor c-Rel in T-lymphocyte-differentiation and effector functions. Clin. Dev. Immunol. 2012, 239368 (2012).","journal-title":"Clin. Dev. Immunol."},{"key":"50880_CR52","doi-asserted-by":"publisher","first-page":"14169","DOI":"10.1073\/pnas.2335979100","volume":"100","author":"S Dubois","year":"2003","unstructured":"Dubois, S. et al. Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells. Proc. Natl. Acad. Sci. USA 100, 14169\u201314174 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"50880_CR53","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/biomedicines11030796","volume":"11","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Immortalized B cells transfected with mRNA of antigen fused to MITD (IBMAM): An effective tool for antigen-specific T-cell expansion and TCR validation. Biomedicines 11, 796 (2023).","journal-title":"Biomedicines"},{"key":"50880_CR54","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.4049\/jimmunol.1403243","volume":"194","author":"J Rasouli","year":"2015","unstructured":"Rasouli, J. et al. Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-beta therapy. J. Immunol. 194, 5085\u20135093 (2015).","journal-title":"J. Immunol."},{"key":"50880_CR55","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/cdd.2013.130","volume":"20","author":"J Zhang","year":"2013","unstructured":"Zhang, J. et al. A novel subset of helper T cells promotes immune responses by secreting GM-CSF. Cell Death Differ. 20, 1731\u20131741 (2013).","journal-title":"Cell Death Differ."},{"key":"50880_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.67","volume":"8","author":"P Bhat","year":"2017","unstructured":"Bhat, P., Leggatt, G., Waterhouse, N. & Frazer, I. H. Interferon-gamma derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 8, e2836 (2017).","journal-title":"Cell Death Dis."},{"key":"50880_CR57","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.4049\/jimmunol.175.8.5043","volume":"175","author":"MA Brehm","year":"2005","unstructured":"Brehm, M. A., Daniels, K. A. & Welsh, R. M. Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells. J. Immunol. 175, 5043\u20135049 (2005).","journal-title":"J. Immunol."},{"key":"50880_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1210836","volume":"14","author":"SL Ford","year":"2023","unstructured":"Ford, S. L. et al. In vitro differentiated human CD4(+) T cells produce hepatocyte growth factor. Front. Immunol. 14, 1210836 (2023).","journal-title":"Front. Immunol."},{"key":"50880_CR59","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1006\/bbrc.1995.1711","volume":"210","author":"B Gesser","year":"1995","unstructured":"Gesser, B. et al. Interleukin-8 induces its own production in CD4+ T lymphocytes: a process regulated by interleukin 10. Biochem. Biophys. Res. Commun. 210, 660\u2013669 (1995).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"50880_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","volume":"75","author":"K Bao","year":"2015","unstructured":"Bao, K. & Reinhardt, R. L. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine 75, 25\u201337 (2015).","journal-title":"Cytokine"},{"key":"50880_CR61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/eji.1830260311","volume":"26","author":"T Jung","year":"1996","unstructured":"Jung, T., Wijdenes, J., Neumann, C., de Vries, J. E. & Yssel, H. Interleukin-13 is produced by activated human CD45RA+ and CD45RO+ T cells: modulation by interleukin-4 and interleukin-12. Eur. J. Immunol. 26, 571\u2013577 (1996).","journal-title":"Eur. J. Immunol."},{"key":"50880_CR62","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/sj.embor.7401099","volume":"8","author":"MF Bachmann","year":"2007","unstructured":"Bachmann, M. F. & Oxenius, A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 8, 1142\u20131148 (2007).","journal-title":"EMBO Rep."},{"key":"50880_CR63","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cellimm.2010.09.011","volume":"266","author":"KO Saunders","year":"2011","unstructured":"Saunders, K. O. et al. Secretion of MIP-1beta and MIP-1alpha by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. Cell Immunol. 266, 154\u2013164 (2011).","journal-title":"Cell Immunol."},{"key":"50880_CR64","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.4049\/jimmunol.1800016","volume":"201","author":"B Li","year":"2018","unstructured":"Li, B., Jones, L. L. & Geiger, T. L. IL-6 Promotes T Cell Proliferation and Expansion under Inflammatory Conditions in Association with Low-Level RORgammat Expression. J. Immunol. 201, 2934\u20132946 (2018).","journal-title":"J. Immunol."},{"key":"50880_CR65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jim.2008.09.021","volume":"340","author":"TK Berthoud","year":"2009","unstructured":"Berthoud, T. K., Dunachie, S. J., Todryk, S., Hill, A. V. & Fletcher, H. A. MIG (CXCL9) is a more sensitive measure than IFN-gamma of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines. J. Immunol. Methods 340, 33\u201341 (2009).","journal-title":"J. Immunol. Methods"},{"key":"50880_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"50880_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111155","volume":"40","author":"R Vu","year":"2022","unstructured":"Vu, R. et al. Wound healing in aged skin exhibits systems-level alterations in cellular composition and cell-cell communication. Cell Rep. 40, 111155 (2022).","journal-title":"Cell Rep."},{"key":"50880_CR68","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"J Moreaux","year":"2004","unstructured":"Moreaux, J. et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148\u20133157 (2004).","journal-title":"Blood"},{"key":"50880_CR69","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3324\/haematol.2016.154062","volume":"102","author":"J Pang","year":"2017","unstructured":"Pang, J. et al. Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression. Haematologica 102, 1273\u20131280 (2017).","journal-title":"Haematologica"},{"key":"50880_CR70","doi-asserted-by":"publisher","first-page":"101178","DOI":"10.1016\/j.tranon.2021.101178","volume":"14","author":"A Deb","year":"2021","unstructured":"Deb, A., Deshmukh, B., Ramteke, P., Bhati, F. K. & Bhat, M. K. Resistin: A journey from metabolism to cancer. Transl. Oncol. 14, 101178 (2021).","journal-title":"Transl. Oncol."},{"key":"50880_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1084\/jem.20020617","volume":"197","author":"CS Schmidt","year":"2003","unstructured":"Schmidt, C. S. et al. Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. J. Exp. Med. 197, 51\u201362 (2003).","journal-title":"J. Exp. Med."},{"key":"50880_CR72","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","volume":"119","author":"M Gupta","year":"2012","unstructured":"Gupta, M. et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 119, 2844\u20132853 (2012).","journal-title":"Blood"},{"key":"50880_CR73","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/cancers14071772","volume":"14","author":"MA Timmins","year":"2022","unstructured":"Timmins, M. A. & Ringshausen, I. Transforming growth factor-beta orchestrates tumour and bystander cells in B-cell non-hodgkin lymphoma. Cancers 14, 1772 (2022).","journal-title":"Cancers"},{"key":"50880_CR74","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.immuni.2018.10.005","volume":"49","author":"M Guilliams","year":"2018","unstructured":"Guilliams, M., Mildner, A. & Yona, S. Developmental and functional heterogeneity of monocytes. Immunity 49, 595\u2013613 (2018).","journal-title":"Immunity"},{"key":"50880_CR75","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1200\/JCO.19.00394","volume":"37","author":"M Bustoros","year":"2019","unstructured":"Bustoros, M. et al. Progression risk stratification of asymptomatic Waldenstrom macroglobulinemia. J. Clin. Oncol. 37, 1403\u20131411 (2019).","journal-title":"J. Clin. Oncol."},{"key":"50880_CR76","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/ejh.12959","volume":"99","author":"K Growkova","year":"2017","unstructured":"Growkova, K. et al. Waldenstrom\u2019s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection. Eur. J. Haematol. 99, 469\u2013478 (2017).","journal-title":"Eur. J. Haematol."},{"key":"50880_CR77","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1182\/blood-2019-130011","volume":"134","author":"J Jakubikova","year":"2019","unstructured":"Jakubikova, J. et al. High-dimensional heterogeneity of Waldenstr\u00f6m macroglobulinemia within Its immune tumor microenvironment. Blood 134, 3975 (2019).","journal-title":"Blood"},{"key":"50880_CR78","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/2326-6066.CIR-14-0218","volume":"3","author":"SR Riddell","year":"2015","unstructured":"Riddell, S. R. Cytotoxic T-cell cytokines put cancer under arrest. Cancer Immunol. Res. 3, 23\u201325 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"50880_CR79","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1535-6108(04)00050-9","volume":"5","author":"CS Mitsiades","year":"2004","unstructured":"Mitsiades, C. S. et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5, 221\u2013230 (2004).","journal-title":"Cancer Cell"},{"key":"50880_CR80","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.18632\/oncotarget.12123","volume":"8","author":"D Vishwamitra","year":"2017","unstructured":"Vishwamitra, D., George, S. K., Shi, P., Kaseb, A. O. & Amin, H. M. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget 8, 1814\u20131844 (2017).","journal-title":"Oncotarget"},{"key":"50880_CR81","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","volume":"120","author":"DJ Kuhn","year":"2012","unstructured":"Kuhn, D. J. et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120, 3260\u20133270 (2012).","journal-title":"Blood"},{"key":"50880_CR82","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1189\/jlb.1003481","volume":"76","author":"PA Ruffini","year":"2004","unstructured":"Ruffini, P. A. et al. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J. Leukoc. Biol. 76, 77\u201385 (2004).","journal-title":"J. Leukoc. Biol."},{"key":"50880_CR83","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2023020254","volume":"141","author":"A Sacco","year":"2023","unstructured":"Sacco, A. et al. Targeting the immune microenvironment in Waldenstrom macroglobulinemia via halting the CD40\/CD40-ligand axis. Blood 141, 2615\u20132628 (2023).","journal-title":"Blood"},{"key":"50880_CR84","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.V97.2.483","volume":"97","author":"MA Frassanito","year":"2001","unstructured":"Frassanito, M. A., Cusmai, A., Iodice, G. & Dammacco, F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97, 483\u2013489 (2001).","journal-title":"Blood"},{"key":"50880_CR85","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/leu.2015.145","volume":"29","author":"T Matthes","year":"2015","unstructured":"Matthes, T. et al. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow. Leukemia 29, 1882\u20131890 (2015).","journal-title":"Leukemia"},{"key":"50880_CR86","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fonc.2018.00147","volume":"8","author":"LV Pham","year":"2018","unstructured":"Pham, L. V., Pogue, E. & Ford, R. J. The role of macrophage\/B-cell interactions in the pathophysiology of B-cell lymphomas. Front Oncol. 8, 147 (2018).","journal-title":"Front Oncol."},{"key":"50880_CR87","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij, O. et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer 1, 493\u2013506 (2020).","journal-title":"Nat. Cancer"},{"key":"50880_CR88","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/2643-3230.BCD-21-0043","volume":"2","author":"A Kaushal","year":"2021","unstructured":"Kaushal, A. et al. Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation, and MyD88-mutant progenitors precede Waldenstrom macroglobulinemia. Blood Cancer Discov. 2, 600\u2013615 (2021).","journal-title":"Blood Cancer Discov."},{"key":"50880_CR89","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330\u20132341 (2018).","journal-title":"N. Engl. J. Med."},{"key":"50880_CR90","first-page":"70","volume":"9","author":"LA Raedler","year":"2016","unstructured":"Raedler, L. A. Darzalex (Daratumumab): first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma. Am. Health Drug Benefits 9, 70\u201373 (2016).","journal-title":"Am. Health Drug Benefits"},{"key":"50880_CR91","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1080\/10428194.2021.1876864","volume":"62","author":"S Khan","year":"2021","unstructured":"Khan, S. et al. A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma. Leuk. Lymphoma 62, 1721\u20131729 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"50880_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03798-6","volume":"20","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenstrom macroglobulinemia. J. Transl. Med. 20, 576 (2022).","journal-title":"J. Transl. Med."},{"key":"50880_CR93","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen, R. G. et al. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br. J. Haematol. 160, 171\u2013176 (2013).","journal-title":"Br. J. Haematol."},{"key":"50880_CR94","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3109\/07357909709047600","volume":"15","author":"CB Kobrin","year":"1997","unstructured":"Kobrin, C. B. & Kwak, L. W. Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Invest. 15, 577\u2013587 (1997).","journal-title":"Cancer Invest."},{"key":"50880_CR95","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-1-4939-0345-0_24","volume":"1139","author":"SC Cha","year":"2014","unstructured":"Cha, S. C., Qin, H., Sakamaki, I. & Kwak, L. Cloning variable region genes of clonal lymphoma immunoglobulin for generating patient-specific idiotype DNA vaccine. Methods Mol. Biol. 1139, 289\u2013303 (2014).","journal-title":"Methods Mol. Biol."},{"key":"50880_CR96","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e1821 (2019).","journal-title":"Cell"},{"key":"50880_CR97","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"50880_CR98","doi-asserted-by":"crossref","unstructured":"Blighe K., Rana S., Lewis M. EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling. (2023).","DOI":"10.32614\/CRAN.package.ggvolcano"},{"key":"50880_CR99","unstructured":"Nazarov V., et al Immunarch: Bioinformatics analysis of T-cell and B-cell immune repertoires. https:\/\/immunarch.com\/, https:\/\/github.com\/immunomind\/immunarch (2023)."},{"key":"50880_CR100","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3389\/fimmu.2019.00299","volume":"10","author":"X Hou","year":"2019","unstructured":"Hou, X. et al. Shorter TCR beta-chains are highly enriched during thymic selection and antigen-driven selection. Front. Immunol. 10, 299 (2019).","journal-title":"Front. Immunol."},{"key":"50880_CR101","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1182\/blood-2010-12-326868","volume":"117","author":"LS Hodge","year":"2011","unstructured":"Hodge, L. S. et al. Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. Blood 117, e190\u2013197 (2011).","journal-title":"Blood"},{"key":"50880_CR102","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1182\/blood.2020008493","volume":"139","author":"MH Qazilbash","year":"2022","unstructured":"Qazilbash, M. H. et al. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood 139, 1289\u20131301 (2022).","journal-title":"Blood"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50880-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50880-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50880-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T10:56:50Z","timestamp":1732618610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50880-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,11]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50880"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50880-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3315017\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,11]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6874"}}